Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
DYT9
MCID: DYS119
MIFTS: 50

Dystonia 9 (DYT9)

Categories: Ear diseases, Eye diseases, Fetal diseases, Genetic diseases, Muscle diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dystonia 9

About this section

MalaCards integrated aliases for Dystonia 9:

Name: Dystonia 9 56 12 73 29 6 15
Choreoathetosis/spasticity, Episodic 56 13 71
Dyt9 56 58 73
Episodic Choreoathetosis/spasticity 58 73
Paroxysmal Dystonic Choreathetosis with Episodic Ataxia and Spasticity 58
Choreoathetosis, Kinesigenic, with Episodic Ataxia and Spasticity 56
Kinesigenic Choreoathetosis with Episodic Ataxia and Spasticity 73
Cse Choreoathetosis, Paroxysmal, with Episodic Ataxia 56
Paroxysmal Choreoathetosis with Episodic Ataxia 73
Muscle Spasticity 43
Dystonia, Type 9 39
Dystonia-9 73
Cse 73

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
variable features
onset at 2 to 15 years
symptoms precipitated by stress, exertion, fatigue, alcohol
some patients respond to acetazolamide


HPO:

31
dystonia 9:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Fetal diseases
Anatomical: Neuronal diseases Eye diseases Ear diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0090044
OMIM 56 601042
OMIM Phenotypic Series 56 PS128100
ICD10 32 G24.8
ICD10 via Orphanet 33 G24.8
UMLS via Orphanet 72 C1832855
Orphanet 58 ORPHA53583
MedGen 41 C1832855
UMLS 71 C1832855
Sources

Summaries for Dystonia 9

About this section
Disease Ontology : 12 A dystonia that is characterized by paroxysmal choreoathetosis and progressive spastic paraplegia, with episodes often precipitated by alcohol, fatigue, or emotional stress, and that has material basis in autosomal dominant inheritance of heterozygous mutation in the solute carrier family 2 member 1 (SLC2A1) gene on chromosome 1p34.

MalaCards based summary : Dystonia 9, also known as choreoathetosis/spasticity, episodic, is related to paroxysmal exertion-induced dyskinesia and glut1 deficiency syndrome 1, and has symptoms including involuntary movements, headache and muscle spasticity. An important gene associated with Dystonia 9 is SLC2A1 (Solute Carrier Family 2 Member 1). The drugs Norepinephrine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are paroxysmal dyskinesia and intellectual disability

OMIM : 56 Dystonia-9 is an autosomal dominant neurologic disorder characterized by childhood onset of paroxysmal choreoathetosis and progressive spastic paraplegia. Most show some degree of cognitive impairment. Other variable features may include seizures, migraine headaches, and ataxia (summary by Weber et al., 2011). (601042)

UniProtKB/Swiss-Prot : 73 Dystonia 9: An autosomal dominant neurologic disorder characterized by childhood onset of paroxysmal choreoathetosis and progressive spastic paraplegia. Most patients show some degree of cognitive impairment. Other variable features may include seizures, migraine headaches, and ataxia.

Sources

Related Diseases for Dystonia 9

About this section

Diseases in the Dystonia family:

Dystonia 12 Dystonia 9
Dystonia, Juvenile-Onset Dystonia 16
Dystonia 21 Dystonia 23
Dystonia 24 Dystonia 25
Dystonia 27 Hereditary Dystonia
Kmt2b-Related Dystonia Rare Dystonia

Diseases related to Dystonia 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 paroxysmal exertion-induced dyskinesia 11.7
2 glut1 deficiency syndrome 1 11.2
3 glucose transporter type 1 deficiency syndrome 11.2
4 neurodegeneration with brain iron accumulation 1 11.1
5 amyotrophic lateral sclerosis 1 10.9
6 argininemia 10.9
7 hyperornithinemia-hyperammonemia-homocitrullinuria syndrome 10.9
8 pseudo-torch syndrome 1 10.9
9 spastic ataxia, charlevoix-saguenay type 10.9
10 purine nucleoside phosphorylase deficiency 10.9
11 combined oxidative phosphorylation deficiency 12 10.9
12 aicardi-goutieres syndrome 10.9
13 neurodegeneration with brain iron accumulation 10.9
14 free sialic acid storage disorders 10.9
15 bain type of x-linked syndromic intellectual disability 10.9
16 x-linked intellectual disability, schimke type 10.9
17 cerebral palsy 10.4
18 pain agnosia 10.3
19 pre-eclampsia 10.3
20 spinal cord injury 10.2
21 homocysteinemia 10.2
22 pulmonary disease, chronic obstructive 10.2
23 encephalopathy 10.2
24 eclampsia 10.2
25 substance abuse 10.2
26 glut1 deficiency syndrome 2 10.1
27 hereditary spastic paraplegia 10.1
28 adcy5-related dyskinesia 10.1
29 spastic paraparesis 10.1
30 paroxysmal choreoathetosis 10.1
31 spasticity 10.1
32 spastic cerebral palsy 10.1
33 traumatic brain injury 10.1
34 atherosclerosis susceptibility 10.1
35 coronary heart disease 1 10.1
36 impotence 10.1
37 hyperglycemia 10.1
38 b-cell lymphoma 10.1
39 hypoglycemia 10.1
40 brain injury 10.0
41 hypertonia 10.0
42 cryohydrocytosis 10.0 STOM SLC2A1
43 bladder cancer 9.9
44 seizures, benign familial neonatal, 1 9.9
45 hair whorl 9.9
46 hypercholesterolemia, familial, 1 9.9
47 papillomatosis, confluent and reticulated 9.9
48 cystathioninuria 9.9
49 retinitis pigmentosa 9.9
50 ataxia and polyneuropathy, adult-onset 9.9

Graphical network of the top 20 diseases related to Dystonia 9:



Diseases related to Dystonia 9
Sources

Symptoms & Phenotypes for Dystonia 9

About this section

Human phenotypes related to Dystonia 9:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 paroxysmal dyskinesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0007166
2 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
3 abnormal pyramidal sign 58 31 frequent (33%) Frequent (79-30%) HP:0007256
4 hyperreflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001347
5 dysarthria 58 31 frequent (33%) Frequent (79-30%) HP:0001260
6 paresthesia 58 31 frequent (33%) Frequent (79-30%) HP:0003401
7 dystonia 58 31 frequent (33%) Frequent (79-30%) HP:0001332
8 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
9 spastic paraplegia 58 31 frequent (33%) Frequent (79-30%) HP:0001258
10 choreoathetosis 58 31 frequent (33%) Frequent (79-30%) HP:0001266
11 diplopia 58 31 frequent (33%) Frequent (79-30%) HP:0000651
12 episodic ataxia 58 31 frequent (33%) Frequent (79-30%) HP:0002131
13 bilateral tonic-clonic seizure 31 very rare (1%) HP:0002069
14 dyskinesia 31 HP:0100660
15 cognitive impairment 31 HP:0100543
16 migraine 31 HP:0002076
17 generalized tonic-clonic seizures 58 Very rare (<4-1%)
18 morphological abnormality of the pyramidal tract 31 HP:0002062

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
cognitive impairment
spasticity
hyperreflexia
dysarthria
involuntary movements
more
Neurologic Peripheral Nervous System:
paresthesias

Head And Neck Eyes:
diplopia

Clinical features from OMIM:

601042

UMLS symptoms related to Dystonia 9:


involuntary movements, headache, muscle spasticity, abnormal pyramidal signs
Sources

Drugs & Therapeutics for Dystonia 9

About this section

Drugs for Dystonia 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3
Baclofen Approved Phase 4 1134-47-0 2284
4
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
5
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
8
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10 Psychotropic Drugs Phase 4
11 rimabotulinumtoxinB Phase 4
12 Antidepressive Agents Phase 4
13 Venlafaxine Hydrochloride Phase 4
14 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
15 abobotulinumtoxinA Phase 4
16 Cholinergic Agents Phase 4
17 Botulinum Toxins Phase 4
18 Botulinum Toxins, Type A Phase 4
19 Neurotransmitter Agents Phase 4
20 Hormones Phase 4
21 GABA Agonists Phase 4
22 Antihypertensive Agents Phase 4
23 Micronutrients Phase 4
24 Trace Elements Phase 4
25 Vitamins Phase 4
26 Vitamin B Complex Phase 4
27 Vasodilator Agents Phase 4
28 Anti-Arrhythmia Agents Phase 4
29 Nutrients Phase 4
30 Folate Phase 4
31 diuretics Phase 4
32 isosorbide-5-mononitrate Phase 4
33 Calcium, Dietary Phase 4
34 Vitamin B9 Phase 4
35 calcium channel blockers Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
37
Calcium Nutraceutical Phase 4 7440-70-2 271
38
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
39
4-Aminopyridine Approved Phase 3 504-24-5 1727
40
Phenylephrine Approved Phase 3 59-42-7 6041
41
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
42
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
43
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
44
Peppermint oil Approved, Investigational Phase 3 8006-90-4
45
Peppermint Approved Phase 3
46
Ethanol Approved Phase 3 64-17-5 702
47
Trichostatin A Experimental Phase 3 58880-19-6
48 Nabiximols Investigational Phase 3 56575-23-6
49 Potassium Channel Blockers Phase 3
50 Antioxidants Phase 3

Interventional clinical trials:

(show top 50) (show all 398)
# Name Status NCT ID Phase Drugs
1 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
2 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
3 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface Unknown status NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
4 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
5 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Unknown status NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
6 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
7 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
8 A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke. Completed NCT00234546 Phase 4 Placebo
9 Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity Completed NCT02757404 Phase 4 Ultrasonography guidance injection of Meditoxin®.;Electrical stimulation guidance injection of Meditoxin®.;Manual needle placement injection of Meditoxin®.
10 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
11 A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity Completed NCT03908580 Phase 4 Meditoxin
12 An Efficacy Comparison of Botulinum Toxin A Injection Into Two Different Sites in Gastrocnemius Muscle for the Treatment of Spastic Patients, Randomized Controlled Trial Completed NCT01278576 Phase 4 BOTOX-A®
13 A Prospective Phase IV, Multicentre, Placebo-controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients Completed NCT00216411 Phase 4 Placebo
14 Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation Among Stroke Patients With Limitation of Finger Extension Due to Spasticity- Pilot Study Completed NCT03549975 Phase 4 Botulinum Toxin Type A 100 unit/Vial (Product)
15 Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb (UL) Spasticity. Completed NCT02321436 Phase 4 Placebo
16 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
17 An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis Completed NCT02969356 Phase 4
18 A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis Completed NCT01964547 Phase 4 Sativex;Placebo
19 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
20 Placebo-Controlled Trial of BOTOX® Versus Zanaflex® for the Treatment of Subjects With Post Stroke Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
21 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
22 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
23 A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment Completed NCT01032239 Phase 4 intrathecal baclofen
24 Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
25 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
26 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
27 A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis Completed NCT01968902 Phase 4
28 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Recruiting NCT02358005 Phase 4
29 A Randomized Controlled Pilot Trial to Compare the Anti-Spastic Efficacy of Nicorandil, Diltiazem and Isosorbide Mononitrate Oral Therapy for Patients Undergoing Coronary Artery Bypass Grafting Using Radial Artery Grafts Recruiting NCT04310995 Phase 4 Nicorandil;Diltiazem Hydrochloride;Isosorbide Mononitrate 50 mg
30 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
31 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen. Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
32 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination Recruiting NCT03367429 Phase 4 Botox
33 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
34 Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke Unknown status NCT00276185 Phase 3 Time delay treatment of botulinum toxin
35 Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3 Unknown status NCT01910363 Phase 2, Phase 3 A2NTX;BOTOX
36 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
37 Comparison of Surface Landmark, Ultrasonography and Electric Stimulation Guidance for Botulinum Toxin Injections in Stroke Patients With Spasticity on Upper Extremities. Unknown status NCT02557737 Phase 3 Botulinum Toxin Type A
38 Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb Unknown status NCT01829763 Phase 3 injection botox
39 Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities Unknown status NCT02469948 Phase 3 Botulinum toxin type A
40 Efficacy and Safety of SPARC0921 in Subjects With Spasticity Completed NCT01457352 Phase 3 SPARC0921;Placebo0921
41 A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity Completed NCT03289702 Phase 3 CORETOX®;BOTOX®
42 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity Completed NCT01575054 Phase 3 Normal Saline
43 Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
44 BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study Completed NCT01603641 Phase 3
45 BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study Completed NCT01603628 Phase 3 Normal Saline (Placebo)
46 BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study Completed NCT01603615 Phase 3
47 BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study Completed NCT01603602 Phase 3 Normal Saline (Placebo)
48 Safety Study of SPARC1104 Completed NCT01797185 Phase 3 SPARC1104 modified dose regimen I;SPARC1104 modified dose regimen II;SPARC1104 modified dose regimen III
49 A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity Completed NCT01915459 Phase 3
50 A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity Completed NCT01945684 Phase 3 Botulinum toxin type A

Search NIH Clinical Center for Dystonia 9

Cochrane evidence based reviews: muscle spasticity

Sources

Genetic Tests for Dystonia 9

About this section

Genetic tests related to Dystonia 9:

# Genetic test Affiliating Genes
1 Dystonia 9 29 SLC2A1
Sources

Anatomical Context for Dystonia 9

About this section

MalaCards organs/tissues related to Dystonia 9:

40
Spinal Cord, Brain, Bone, Testes, Cortex, Lung
Sources

Publications for Dystonia 9

About this section

Articles related to Dystonia 9:

(show all 22)
# Title Authors PMID Year
1
Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. 56 6 61
21832227 2011
2
A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. 6 56
8808284 1996
3
Glucose Transporter Type 1 Deficiency Syndrome 6 61
20301603 2002
4
EFNS guidelines on diagnosis and treatment of primary dystonias. 6
20482602 2011
5
Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. 6
19798636 2009
6
Paroxysmal movement disorders in GLUT1 deficiency syndrome. 6
18606970 2008
7
Hereditary Dystonia Overview 6
20301334 2003
8
Clinical and molecular genetics of primary dystonias. 56
10737119 1998
9
Familial periodic cerebellar ataxia: a problem of cerebellar intracellular pH homeostasis. 56
1575453 1992
10
SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia. 61
30616884 2019
11
Reliability of clinical diagnosis of dystonia. 61
25402591 2014
12
Overview of primary monogenic dystonia. 61
22166420 2012
13
In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. 61
21370265 2011
14
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. 61
20816032 2010
15
The monogenic primary dystonias. 61
19578124 2009
16
[Botulinum A toxin treatment in patients with oromandibular dystonia with concomitant malnutrition]. 61
15098332 2003
17
Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. 61
12162386 2002
18
Evaluation and treatment of dystonia. 61
10963502 2000
19
Genetics of primary dystonia. 61
12194383 1999
20
[Ataxia telangiectasia: review of 13 new cases]. 61
8852005 1996
21
Bilateral striatal lesions in childhood. 61
8292209 1993
22
[Symptomatology of the involuntary movement]. 61
2012697 1991
Sources

Variations for Dystonia 9

About this section

ClinVar genetic disease variations for Dystonia 9:

6 (show top 50) (show all 96) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SLC2A1 NM_006516.3(SLC2A1):c.161dup (p.Ser55fs)duplication Pathogenic 619980 rs1557646867 1:43396830-43396831 1:42931159-42931160
2 SLC2A1 NM_006516.3(SLC2A1):c.634C>T (p.Arg212Cys)SNV Pathogenic 37300 rs387907312 1:43395589-43395589 1:42929918-42929918
3 SLC2A1 NM_006516.3(SLC2A1):c.667C>T (p.Arg223Trp)SNV Pathogenic 207193 rs796053248 1:43395556-43395556 1:42929885-42929885
4 SLC2A1 NM_006516.3(SLC2A1):c.19-2A>GSNV Pathogenic 207225 rs796053272 1:43408994-43408994 1:42943323-42943323
5 SLC2A1 NM_006516.3(SLC2A1):c.997C>T (p.Arg333Trp)SNV Pathogenic/Likely pathogenic 198842 rs80359825 1:43394680-43394680 1:42929009-42929009
6 SLC2A1 NM_006516.3(SLC2A1):c.1372C>T (p.Arg458Trp)SNV Pathogenic/Likely pathogenic 96708 rs13306758 1:43392819-43392819 1:42927148-42927148
7 SLC2A1 NM_006516.3(SLC2A1):c.376C>T (p.Arg126Cys)SNV Pathogenic/Likely pathogenic 16118 rs80359818 1:43396437-43396437 1:42930766-42930766
8 SLC2A1 NM_006516.3(SLC2A1):c.653G>A (p.Arg218His)SNV Conflicting interpretations of pathogenicity 546093 rs374080633 1:43395570-43395570 1:42929899-42929899
9 SLC2A1 NM_006516.3(SLC2A1):c.188C>T (p.Thr63Met)SNV Conflicting interpretations of pathogenicity 406880 rs200828053 1:43396804-43396804 1:42931133-42931133
10 SLC2A1 NM_006516.3(SLC2A1):c.18+12G>TSNV Conflicting interpretations of pathogenicity 139154 rs587781171 1:43424293-43424293 1:42958622-42958622
11 SLC2A1 NM_006516.3(SLC2A1):c.27G>A (p.Thr9=)SNV Conflicting interpretations of pathogenicity 139155 rs34025424 1:43408984-43408984 1:42943313-42943313
12 SLC2A1 NM_006516.3(SLC2A1):c.777C>T (p.Ile259=)SNV Conflicting interpretations of pathogenicity 95417 rs78388808 1:43395354-43395354 1:42929683-42929683
13 SLC2A1 NM_006516.3(SLC2A1):c.764A>C (p.Lys255Thr)SNV Conflicting interpretations of pathogenicity 159929 rs5811 1:43395367-43395367 1:42929696-42929696
14 SLC2A1 NM_006516.3(SLC2A1):c.680-10G>TSNV Conflicting interpretations of pathogenicity 159926 rs587784394 1:43395461-43395461 1:42929790-42929790
15 SLC2A1 NM_006516.3(SLC2A1):c.906G>T (p.Gly302=)SNV Conflicting interpretations of pathogenicity 198545 rs55693364 1:43394947-43394947 1:42929276-42929276
16 SLC2A1 NM_006516.3(SLC2A1):c.1016T>C (p.Ile339Thr)SNV Conflicting interpretations of pathogenicity 198843 rs141619735 1:43394661-43394661 1:42928990-42928990
17 SLC2A1 NM_006516.3(SLC2A1):c.313G>A (p.Val105Met)SNV Conflicting interpretations of pathogenicity 207189 rs577667739 1:43396500-43396500 1:42930829-42930829
18 SLC2A1 NM_006516.3(SLC2A1):c.274C>A (p.Arg92=)SNV Conflicting interpretations of pathogenicity 207181 rs202060209 1:43396718-43396718 1:42931047-42931047
19 SLC2A1 NM_006516.3(SLC2A1):c.138G>C (p.Gln46His)SNV Conflicting interpretations of pathogenicity 207187 rs149998596 1:43396854-43396854 1:42931183-42931183
20 SLC2A1 NM_006516.3(SLC2A1):c.125A>C (p.Glu42Ala)SNV Conflicting interpretations of pathogenicity 207186 rs748082803 1:43396867-43396867 1:42931196-42931196
21 SLC2A1 NM_006516.3(SLC2A1):c.1395C>T (p.Ser465=)SNV Conflicting interpretations of pathogenicity 212203 rs75852730 1:43392796-43392796 1:42927125-42927125
22 SLC2A1 NM_006516.3(SLC2A1):c.1034C>T (p.Ala345Val)SNV Conflicting interpretations of pathogenicity 212202 rs769943554 1:43394643-43394643 1:42928972-42928972
23 SLC2A1 NM_006516.3(SLC2A1):c.987G>A (p.Glu329=)SNV Conflicting interpretations of pathogenicity 286943 rs201989024 1:43394690-43394690 1:42929019-42929019
24 SLC2A1 NM_006516.3(SLC2A1):c.312C>G (p.Phe104Leu)SNV Conflicting interpretations of pathogenicity 297381 rs76672402 1:43396501-43396501 1:42930830-42930830
25 SLC2A1 NM_006516.3(SLC2A1):c.132C>T (p.Tyr44=)SNV Uncertain significance 297382 rs886046341 1:43396860-43396860 1:42931189-42931189
26 SLC2A1 NM_006516.3(SLC2A1):c.*1611T>CSNV Uncertain significance 297350 rs1057515457 1:43391101-43391101 1:42925430-42925430
27 SLC2A1 NM_006516.3(SLC2A1):c.*1337A>GSNV Uncertain significance 297354 rs113441673 1:43391375-43391375 1:42925704-42925704
28 SLC2A1 NM_006516.3(SLC2A1):c.*1147G>CSNV Uncertain significance 297361 rs886046332 1:43391565-43391565 1:42925894-42925894
29 SLC2A1 NM_006516.3(SLC2A1):c.*1337A>CSNV Uncertain significance 297355 rs113441673 1:43391375-43391375 1:42925704-42925704
30 SLC2A1 NM_006516.3(SLC2A1):c.*1205C>TSNV Uncertain significance 297359 rs886046331 1:43391507-43391507 1:42925836-42925836
31 SLC2A1 NM_006516.3(SLC2A1):c.*514G>TSNV Uncertain significance 297373 rs886046339 1:43392198-43392198 1:42926527-42926527
32 SLC2A1 NM_006516.3(SLC2A1):c.411A>G (p.Thr137=)SNV Uncertain significance 297380 rs753500924 1:43396402-43396402 1:42930731-42930731
33 SLC2A1 NM_006516.3(SLC2A1):c.172C>T (p.Pro58Ser)SNV Uncertain significance 538681 rs765479065 1:43396820-43396820 1:42931149-42931149
34 SLC2A1 NM_006516.4(SLC2A1):c.*216C>TSNV Uncertain significance 876720 1:43392496-43392496 1:42926825-42926825
35 SLC2A1 NM_006516.4(SLC2A1):c.*107G>ASNV Uncertain significance 876721 1:43392605-43392605 1:42926934-42926934
36 SLC2A1 NM_006516.4(SLC2A1):c.*92G>ASNV Uncertain significance 873892 1:43392620-43392620 1:42926949-42926949
37 SLC2A1 NM_006516.3(SLC2A1):c.192C>G (p.Leu64=)SNV Uncertain significance 626018 rs762583668 1:43396800-43396800 1:42931129-42931129
38 SLC2A1 NM_006516.3(SLC2A1):c.75G>A (p.Gln25=)SNV Uncertain significance 626019 rs1557651193 1:43408936-43408936 1:42943265-42943265
39 SLC2A1 NM_006516.3(SLC2A1):c.1062G>A (p.Ala354=)SNV Uncertain significance 806115 1:43394615-43394615 1:42928944-42928944
40 SLC2A1 NM_006516.4(SLC2A1):c.668G>A (p.Arg223Gln)SNV Uncertain significance 842670 1:43395555-43395555 1:42929884-42929884
41 SLC2A1 NM_006516.4(SLC2A1):c.*1321T>ASNV Uncertain significance 873784 1:43391391-43391391 1:42925720-42925720
42 SLC2A1 NM_006516.4(SLC2A1):c.*1079T>GSNV Uncertain significance 875681 1:43391633-43391633 1:42925962-42925962
43 SLC2A1 NM_006516.4(SLC2A1):c.*775A>GSNV Uncertain significance 876676 1:43391937-43391937 1:42926266-42926266
44 SLC2A1 NM_006516.4(SLC2A1):c.*609G>CSNV Uncertain significance 873841 1:43392103-43392103 1:42926432-42926432
45 SLC2A1 NM_006516.4(SLC2A1):c.*413G>ASNV Uncertain significance 875726 1:43392299-43392299 1:42926628-42926628
46 SLC2A1 NM_006516.4(SLC2A1):c.*368A>CSNV Uncertain significance 875727 1:43392344-43392344 1:42926673-42926673
47 SLC2A1 NM_006516.4(SLC2A1):c.332G>T (p.Gly111Val)SNV Uncertain significance 875828 1:43396481-43396481 1:42930810-42930810
48 SLC2A1 NM_006516.4(SLC2A1):c.279G>A (p.Arg93=)SNV Uncertain significance 876820 1:43396534-43396534 1:42930863-42930863
49 SLC2A1 NM_006516.4(SLC2A1):c.-129G>TSNV Uncertain significance 875875 1:43424451-43424451 1:42958780-42958780
50 SLC2A1 NM_006516.4(SLC2A1):c.-194G>ASNV Uncertain significance 875876 1:43424516-43424516 1:42958845-42958845

UniProtKB/Swiss-Prot genetic disease variations for Dystonia 9:

73
# Symbol AA change Variation ID SNP ID
1 SLC2A1 p.Arg126Cys VAR_054757 rs80359818
2 SLC2A1 p.Arg212Cys VAR_065213 rs387907312

Sources

Expression for Dystonia 9

About this section
Search GEO for disease gene expression data for Dystonia 9.
Sources

Pathways for Dystonia 9

About this section
Sources

GO Terms for Dystonia 9

About this section

Cellular components related to Dystonia 9 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome GO:0042470 8.96 STOM SLC2A1
2 intercalated disc GO:0014704 8.62 SLC2A1 MYH1

Biological processes related to Dystonia 9 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chloride transmembrane transport GO:1902476 9.16 GABRE CLCN6
2 chloride transport GO:0006821 8.96 GABRE CLCN6
3 ion transmembrane transport GO:0034220 8.8 SCN3A GABRE CLCN6
Sources

Sources for Dystonia 9

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....